Stock Spotlight

Stock Spotlight: Fisher & Paykel Healthcare (ASX:FPH)

Stock Spotlight: Fisher & Paykel Healthcare (ASX:FPH)

Key stats

$19.977B
Market cap
$33.84
Share price
13.88%
1 year return
58.16
P/E ratio
1.15%
Dividend yield
0.73
Beta
0.58
EPS
PEG ratio
0.01%
Short interest
Healthcare
Industry

Source: Yahoo Finance. Data as of 19/08/25.

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.

Price Performance

Growth Potential

  • Global leader in invasive and non-invasive inhalation, nasal high flow therapy and during surgery.
  • Strong global market position in a significantly under-penetrated treatment of sleep apnea market and chronic obstructive pulmonary disease.
  • Increasing uptake of Nasal high-flow (NHF) therapy and consumables growth on the back of this.
  • High barriers to entry in establishing global distribution channels.
  • Strong R&D program ensuring new product releases and FPH remains ahead of competitors.
  • Bolt-on acquisitions to supplement organic growth.

Key Risks

  • Consolidation / normalization of sales post the COVID-19 driven demand.
  • Disruptive technology leading to better patient compliance.
  • Product recall leading to reputational damage.
  • Competitive threats leading to market share loss.
  • Disappointing growth (company and industry specific).
  • Adverse currency movements.
  • FPH needs to grow to maintain its high PE trading multiple. Therefore, any impact on growth may put pressure on FPH’s valuation.

Frequently asked questions

This article is general information only and does not take into account your objectives, financial situation or needs. It is not a recommendation to buy or sell any security. Past performance is not a reliable indicator of future performance. Consider seeking financial, legal and taxation advice before investing.

Newsletter

Get our insights in your inbox

Join the Sharewise newsletter for new market insights and stock spotlights, plus invites to company webinars and Stocks and Sips evenings.

More articles

All news →

Want more than one article's worth?

Sharewise clients get ongoing research, Advisor access and execution across ASX, US and global markets.

Explore our services →